This article is for informational purposes only. Cannabis can interact with many medications. Always consult your healthcare provider before combining cannabinoid products with any medication.
By Take Hemp Gummies Safety Desk | Last verified: July 2026
Cannabinoids During Pregnancy and Breastfeeding: Safety Considerations
Overview: Why Pregnancy and Breastfeeding Require Special Caution
Pregnancy and breastfeeding create a unique physiological context in which cannabinoid exposure extends beyond the individual user to include the developing fetus and nursing infant. Unlike general population safety, the stakes involve neurodevelopmental timing, organ formation, and long-term outcomes that cannot be fully predicted from short-term adult studies.
Current evidence does not support the safety of cannabis or cannabinoid products (CBD, THC, delta-8, or minor cannabinoids) during pregnancy or breastfeeding. Major medical organizations—including the American College of Obstetricians and Gynecologists (ACOG), the American Academy of Pediatrics (AAP), and the Substance Abuse and Mental Health Services Administration (SAMHSA)—recommend against cannabinoid use in these periods.
This article explains why, covers the mechanisms of risk, and offers guidance for individuals considering cannabinoid use before or after pregnancy.
Mechanism of Risk: How Cannabinoids Cross the Placenta and Enter Breast Milk
Transplacental Transfer
Cannabinoids are highly lipophilic (fat-soluble) molecules that readily cross the placental barrier. THC and CBD both accumulate in fetal tissue, with THC concentrations in fetal blood and amniotic fluid reaching levels comparable to or higher than maternal serum. The developing brain—with its rapid neurogenesis, synaptogenesis, and myelination—may be particularly vulnerable to cannabinoid signaling during critical windows of development.
Animal models suggest THC exposure during pregnancy can disrupt endocannabinoid system signaling, which plays a role in fetal neural development, immune function, and circuit formation. Human data remain limited, but observational studies have noted associations between prenatal cannabis use and altered birth outcomes, including reduced birth weight and preterm delivery.
Transfer via Breast Milk
Both THC and CBD are secreted into breast milk at concentrations that can exceed maternal plasma levels due to their lipophilicity and long half-lives. A nursing infant has immature hepatic metabolism (CYP3A4 and CYP2C19 enzymes are not fully developed until 6–12 months of age), meaning cannabinoids may accumulate to higher relative concentrations and persist longer in the infant than in the mother.
Infant exposure via breast milk can result in measurable cannabinoid levels in infants’ blood and effects on motor development, feeding behavior, and sleep-wake cycles in observational studies. Long-term neurodevelopmental sequelae have not been prospectively studied.
Drug Interactions During Pregnancy and Lactation
Pregnant and breastfeeding individuals often use medications for nausea, anxiety, depression, seizures, or other conditions. Cannabinoids interact with several drug classes commonly prescribed in these periods:
Antiemetics (Nausea Medications)
Ondansetron, metoclopramide, and other antiemetics are frequently used for pregnancy-related nausea and hyperemesis gravidarum. Both THC and ondansetron inhibit CYP3A4 and CYP2C19, potentially increasing antiemetic levels and side effects. Additionally, cannabinoids themselves can affect gastric motility and appetite signals, potentially complicating nausea management.
Selective Serotonin Reuptake Inhibitors (SSRIs)
SSRIs such as sertraline, paroxetine, and fluoxetine are common treatments for prenatal and postpartum depression and anxiety. Cannabinoids inhibit CYP2D6 and CYP3A4, potentially increasing SSRI levels and risk of serotonin syndrome, tremor, or agitation. These effects are particularly concerning during the third trimester and postpartum period.
Anticonvulsants
Pregnant individuals with epilepsy or seizure disorders rely on medications such as phenytoin, levetiracetam, or valproic acid. Cannabinoids may induce or inhibit CYP3A4 and CYP2C9, altering anticonvulsant levels and seizure control. Even brief fluctuations in seizure medication concentrations pose serious risks during pregnancy.
Corticosteroids and Immunosuppressants
Pregnant individuals with autoimmune conditions or those at risk of preeclampsia may use corticosteroids or other immunosuppressive agents. Cannabinoids modulate immune and inflammatory pathways; combined use could amplify immunosuppression or alter placental immune tolerance.
Interaction Reference Table
| Medication Class / Drug | Interaction Mechanism | Severity | Recommended Action |
|---|---|---|---|
| Ondansetron, Metoclopramide (Antiemetics) | CYP3A4 / CYP2C19 inhibition; altered GI motility | Moderate–High | Avoid combination; discuss alternative nausea management with OB-GYN |
| Sertraline, Paroxetine, Fluoxetine (SSRIs) | CYP2D6 / CYP3A4 inhibition; serotonin syndrome risk | Moderate–High | Avoid; discuss mental health support with psychiatry and OB-GYN |
| Phenytoin, Levetiracetam, Valproic Acid (Anticonvulsants) | CYP3A4 / CYP2C9 induction or inhibition; altered seizure control | High | Contraindicated; seizure control during pregnancy is critical |
| Prednisone, Methylprednisolone (Corticosteroids) | Immunomodulation; potential additive immunosuppression | Moderate | Avoid; consult prescribing physician and OB-GYN before use |
| Warfarin, Apixaban (Anticoagulants) | CYP3A4 inhibition; altered anticoagulant metabolism | High | Contraindicated; anticoagulation levels must remain stable during pregnancy |
| Prenatal Vitamins (Iron, Folic Acid, Calcium) | Potential CYP450 competition; reduced absorption | Low–Moderate | Separate dosing by 2+ hours; prioritize prenatal vitamins |
At-Risk Populations: Who Should Avoid Cannabinoids During Pregnancy and Breastfeeding
All Pregnant Individuals
Pregnancy represents a contraindication to cannabinoid use across all trimesters. The developing brain is most vulnerable to endocannabinoid system disruption during the first and second trimesters when major neural structures form. However, third-trimester exposure carries risks for preterm labor, reduced birth weight, and neonatal withdrawal-like symptoms.
Breastfeeding Individuals
Individuals actively breastfeeding should avoid all cannabinoid products. THC and CBD accumulate in breast milk and persist in nursing infants who cannot metabolize them efficiently. Cessation should occur at least 2–4 weeks before initiating breastfeeding to allow maternal cannabinoid levels to decline (though trace amounts may persist longer).
Individuals Planning Pregnancy
Those attempting conception should discontinue cannabinoid use 4–6 weeks before trying to conceive. This allows clearance from the body and reduces the risk of early embryonic exposure during the critical window between conception and implantation.
Individuals with Co-Occurring Conditions
Pregnant individuals with depression, anxiety, or pain conditions face additional complexity. Cannabinoids should not be substituted for evidence-based psychiatric or pain management. A coordinated care plan involving OB-GYN, psychiatry, and pain management specialists is essential.
Safe Use Guidelines: What to Do Instead
Before Pregnancy
- Plan ahead: If you use cannabinoid products, discuss your fertility intentions with your healthcare provider 4–6 weeks in advance.
- Discontinue gradually: Abrupt cessation may cause withdrawal symptoms; work with your provider on a safe tapering schedule if needed.
- Identify alternatives: For pain, anxiety, or insomnia, explore non-cannabinoid options (therapy, physical therapy, safe OTC options) with your provider.
During Pregnancy
- Do not use: Avoid all cannabis, THC, CBD, delta-8, and other cannabinoids.
- Report past use: Disclose any cannabinoid use before you knew you were pregnant to your OB-GYN; do not delay prenatal care out of concern.
- Evidence-based alternatives: Work with your healthcare team on safe options for nausea, anxiety, depression, or pain (ginger, acupuncture, approved medications, cognitive-behavioral therapy).
Breastfeeding
- Avoid all cannabinoids: Do not resume use while breastfeeding. THC and CBD enter breast milk and can affect infant development.
- Timing after cessation: If you used cannabinoids before breastfeeding, allow 2–4 weeks of abstinence before beginning nursing. Longer abstinence (6–8 weeks) reduces infant exposure further.
- If supplementing or formula feeding: Use of cannabinoids is still not recommended due to unknown long-term infant effects, but risk of direct infant exposure is lower.
When to Seek Help: Warning Signs and Emergency Guidance
Contact your healthcare provider or call Poison Control (1-800-222-1222 in the US) if you or your infant experience:
- Accidental cannabinoid ingestion during pregnancy (especially high-dose edibles)
- Signs of infant cannabinoid exposure: poor feeding, unusual sleepiness, tremor, irritability, or developmental delay
- Withdrawal symptoms after stopping cannabinoids (tremor, anxiety, insomnia, nausea)
- Worsening depression, anxiety, or suicidal thoughts during or after pregnancy (seek immediate mental health support; cannabinoids are not a solution)
- Signs of serotonin syndrome if combining SSRIs and cannabinoids: confusion, rapid heartbeat, muscle rigidity, high fever
Additionally, report any cannabinoid use to your OB-GYN at your first prenatal visit. Honest disclosure allows your healthcare team to monitor
Related reading: CBD During Pregnancy or Breastfeeding: What the FDA Says and What Is Unknown | THC Detox Science: How Cannabinoids Leave the Body